Aerie Pharmaceuticals (NASDAQ:AERI) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Aerie Pharmaceuticals (NASDAQ:AERI) issued its quarterly earnings results on Wednesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.02), Fidelity Earnings reports. The company had revenue of $18.54 million during the quarter, compared to analyst estimates of $17.59 million. Aerie Pharmaceuticals had a negative net margin of 478.81% and a negative return on equity of 89.52%.

AERI traded up $0.75 during trading on Friday, reaching $19.23. The company’s stock had a trading volume of 2,084,600 shares, compared to its average volume of 892,659. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.52. Aerie Pharmaceuticals has a 52-week low of $17.51 and a 52-week high of $50.10. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.14 and a beta of 0.51. The company’s fifty day moving average price is $21.03 and its 200-day moving average price is $27.38.

In other Aerie Pharmaceuticals news, CEO Vicente Anido, Jr. purchased 26,250 shares of the business’s stock in a transaction on Monday, September 9th. The stock was bought at an average cost of $19.01 per share, for a total transaction of $499,012.50. Following the acquisition, the chief executive officer now owns 195,631 shares of the company’s stock, valued at approximately $3,718,945.31. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Foresite Capital Fund Ii, L.P. purchased 46,153 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average price of $23.45 per share, with a total value of $1,082,287.85. The disclosure for this purchase can be found here. Insiders have purchased a total of 562,698 shares of company stock valued at $13,088,866 over the last 90 days. Insiders own 8.71% of the company’s stock.

AERI has been the topic of several recent research reports. Cowen restated an “outperform” rating and issued a $50.00 price target (down previously from $105.00) on shares of Aerie Pharmaceuticals in a research report on Thursday. Citigroup restated an “outperform” rating and issued a $45.00 price target (down previously from $65.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, August 8th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 30th. Piper Jaffray Companies dropped their price target on Aerie Pharmaceuticals from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, JMP Securities dropped their price target on Aerie Pharmaceuticals to $41.00 and set an “outperform” rating on the stock in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $44.92.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Recommended Story: What is a balanced fund?

Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.